Cargando…

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

BACKGROUND: Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortellini, Alessio, Cannita, Katia, Parisi, Alessandro, Lanfiuti Baldi, Paola, Venditti, Olga, D’Orazio, Carla, Dal Mas, Antonella, Calvisi, Giuseppe, Giordano, Aldo V, Vicentini, Vincenzo, Vicentini, Roberto, Felicioni, Lara, Marchetti, Antonio, Buttitta, Fiamma, Russo, Antonio, Ficorella, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438145/ https://www.ncbi.nlm.nih.gov/pubmed/30988620 http://dx.doi.org/10.2147/OTT.S194745

Ejemplares similares

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
por: Marchetti, Antonio, et al.
Publicado: (2019)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy
por: Cortellini, Alessio, et al.
Publicado: (2017)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations
por: Cocciolone, Valentina, et al.
Publicado: (2018)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
por: Cortellini, Alessio, et al.
Publicado: (2020)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Single‐institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non‐small cell lung cancer patients treated with first‐line chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2018)

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity
por: Cianci, G, et al.
Publicado: (2003)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
por: Bruera, Gemma, et al.
Publicado: (2019)

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
por: Bruera, Gemma, et al.
Publicado: (2014)

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: A “hypothesis‐generator” preliminary report
por: Cortellini, Alessio, et al.
Publicado: (2019)

Mutational Profile of GNAQ (Q209) in Human Tumors
por: Lamba, Simona, et al.
Publicado: (2009)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2017)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
por: Cocciolone, Valentina, et al.
Publicado: (2017)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer()()
por: Gasparini, Giampietro, et al.
Publicado: (2014)

POLE exonuclease domain mutations in endometrial carcinoma: a case report
por: Pasciuto, Maria Paola, et al.
Publicado: (2023)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020)

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

What Is Known about Theragnostic Strategies in Colorectal Cancer
por: Parisi, Alessandro, et al.
Publicado: (2021)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
por: Lazzaro, Carlo, et al.
Publicado: (2023)

Physical Exercise and Quality of Life in Breast Cancer Survivors
por: VALENTI, Marco, et al.
Publicado: (2008)

Family history of cancer and DNA damage response genes: Two sides of the same coin?
por: Cortellini, Alessio, et al.
Publicado: (2018)

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
por: Cortellini, Alessio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g77vous6ivov9k8eam1dbqt90q